28177-79-9

Basic information

• Product Name: 2-HYDROXY-3-NITRO-BENZONITRILE
• Synonyms: 2-HYDROXY-3-NITRO-BENZONITRILE;Benzonitrile, 2-hydroxy-3-nitro-
• CAS NO: 28177-79-9
• Molecular Formula: C₇H₄N₂O₃
• Molecular Weight: 164.12
• Mol File: 28177-79-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 265.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.49±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.94±0.24(Predicted)
• CAS DataBase Reference: 2-HYDROXY-3-NITRO-BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HYDROXY-3-NITRO-BENZONITRILE(28177-79-9)
• EPA Substance Registry System: 2-HYDROXY-3-NITRO-BENZONITRILE(28177-79-9)

Safety Data

• Hazardous Substances Data: 28177-79-9(Hazardous Substances Data)

Usage

General Description

2-Hydroxy-3-nitro-benzonitrile is a chemical compound with the molecular formula C7H4N2O3. It is a yellow crystalline solid that is commonly used as an intermediate in the synthesis of various organic compounds. It is also known for its potential use as a building block for pharmaceuticals and agrochemicals. In addition, 2-hydroxy-3-nitro-benzonitrile has been studied for its potential biological activities, including its antimicrobial and antifungal properties. 2-HYDROXY-3-NITRO-BENZONITRILE is of interest to the scientific community for its versatile applications and potential medicinal uses.

Upstream product

• 611-20-1 salicylonitrile 
• 7697-37-2 nitric acid 
• 64-19-7 acetic acid 
• 151-50-8 potassium cyanide 
• 528-29-0 1,2-Dinitrobenzene 

Downstream Products

• 67608-57-5 6-cyano-2-aminophenol 
• 121001-06-7 2-methoxy-3-nitrobenzonitrile 
• 1609393-80-7 4-((3-cyano-2-methoxyphenyl)amino)-6-(cyclopropanecarboxamido)-N-trideuteromethylpyridazine-3-carboxamide 
• 1609393-84-1 C₂₁H₂₀N₈O₃ 
• 1609394-59-3 4-((3-cyano-2-methoxyphenyl)amino)-N-methyl-6-(pyridin-2-ylamino)pyridazine-3-carboxamide 
• 1609394-58-2 6-chloro-4-((3-cyano-2-methoxyphenyl)amino)-N-methylpyridazine-3-carboxamide 
• 1609394-52-6 6-chloro-4-((3-cyano-2-methoxyphenyl)amino)-N-trideuteromethylpyridazine-3-carboxamide 
• 725718-10-5 3-amino-2-methoxybenzonitrile 
• 55586-26-0 3-hydroxy-4-aminobenzonitrile 
• 95082-02-3 7-nitrobenzo[d]oxazol-2-amine 

Relevant articles and documents

Synthesis and evaluation of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives as xanthine oxidase inhibitors

This study mainly focused on the modification of the X2 position in febuxostat analogs. A series of 1-phenyl-1H-1,2,3-triazole-4-carboxylic acid derivatives (1a-s) with an N atom occupying the X2 position was designed and synthesized. Evaluation of their inhibitory potency in vitro on xanthine oxidase indicated that these compounds exhibited micromolar level potencies, with IC50 values ranging from 0.21?μM to 26.13?μM. Among them, compound 1s (IC50?=?0.21?μM) showed the most promising inhibitory effects and was 36-fold more potent than allopurinol, but was still 13-fold less potent than the lead compound Y-700, which meant that a polar atom fused at the X2 position could be unfavorable for potency. The Lineweaver-Burk plot revealed that compound 1s acted as a mixed-type xanthine oxidase inhibitor. Analysis of the structure-activity relationships demonstrated that a more lipophilic ether tail (e.g., meta-methoxybenzoxy) at the 4′-position could benefit the inhibitory potency. Molecular modeling provided a reasonable explanation for the structure–activity relationships observed in this study.

NOVEL AMIDE COMPOUNDS WITH MCH ANTAGONISTIC EFFECT AND MEDICAMENTS COMPRISING SAID COMPOUNDS

The invention relates to amide compounds of general formula (I), in which the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. The invention further relates to medicaments comprising at least one of said amides. Said medicaments are suitable for the treatment of metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia, and diabetes as a result of the MCH receptor antagonism.

IL-8 RECEPTOR ANTAGONISTS

Novel IL-8 receptor antagonists and methods of using them are provided.